Figure 1.

Flowchart of unique statin users included in the study. The Norwegian Prescription Database 2004/2006. *Some patients will be exposed to both short-term and long-term CYP3A4 inhibition during their period of statin use and will therefore be identified as both short-term and long-term co-medicated patients. The sum of, for example, n₂₀₀₄ short-term co-medication and n₂₀₀₄ long-term co-medication will be bigger than the actual sum of individuals overall exposed to CYP3A4 inhibitors in 2004